Neera K. Dahl, M.D., Ph.D.

A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).

The purpose of this study is to estimate the prevalence of PKD1 gene variant groups in the ADPKD population and describe the demographic and clinical characteristics of ADPKD by PKD1 gene variant group.

The purpose of this study is to analyze clinical, radiological, and genotypic data of a cohort of 384 patients with cystic kidney disease who underwent Renasight (Natera) genetic testing at Mayo Clinic (dataset will consist of patients from IRB# 13-003971 who consented have their information/samples stored and used in future research at Mayo Clinic or patients that participated in a previous study of the RenaCARE application (21-02744) and who orally consent to participate in this research (203), and those who had clinical testing with Renasight at Mayo Rochester (203) and Jacksonville (118)).

The purpose of this study is to assess the ability of 18F-sodium fluoride positron emission tomography ( 18F-NaF PET)/computed tomography (CT) and Diffusion magnetic resonance imaging (MRI) to differentiate between healthy subjects and ADPKD subjects at baseline

A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).